BioCentury
ARTICLE | Company News

Orphan Drug designation for Espero's long-acting anticoagulant

March 14, 2019 11:53 PM UTC

Espero said FDA granted Orphan Drug designation to tecarfarin to prevent systemic thromboembolism of cardiac origin in patients with end-stage rental disease and atrial fibrillation. The company said there are no approves therapies for ESRD patients with AF...